Information Sources

Credits & Sources

The information provided on this website is based on peer-reviewed scientific research and clinical guidelines from leading pharmacogenomics organizations.

Major Organizations & Guidelines

U.S. Food & Drug Administration (FDA)

Provides pharmacogenomic biomarker information for medications and labels regarding genetic testing requirements or recommendations.

Visit FDA Database

Clinical Pharmacogenetics Implementation Consortium (CPIC)

Provides evidence-based guidelines for gene-drug dosing relationships based on peer-reviewed literature.

View CPIC Guidelines

PharmGKB

A comprehensive database of genetic variants affecting drug response, maintained by Stanford University.

Visit PharmGKB

Dutch Pharmacogenetics Working Group (DPWG)

Provides pharmacogenetics-based dosing guidelines widely used in Europe and adopted by many healthcare systems.

View DPWG Guidelines

Drug-Specific Information Sources

The medication database on this website is compiled from the following clinical guidelines and resources:

CYP2C19 Medications

Medications: Citalopram, Escitalopram, Sertraline, Clopidogrel, Omeprazole

  • CPIC Guidelines for CYP2C19 and Citalopram/Escitalopram (2017)
  • CPIC Guidelines for Clopidogrel and CYP2C19 (2022)
  • FDA Labeling for Plavix (Clopidogrel) - Boxed Warning
  • DPWG Guidelines for Omeprazole and CYP2C19

CYP2D6 Medications

Medications: Codeine, Tramadol, Metoprolol, Tamoxifen

  • FDA Safety Communication on Codeine and CYP2D6 (2017)
  • CPIC Guidelines for Codeine and CYP2D6 (2014)
  • CPIC Guidelines for Tamoxifen and CYP2D6 (2019)
  • DPWG Guidelines for Metoprolol and CYP2D6

SLCO1B1 Medications (Statins)

Medications: Simvastatin, Atorvastatin, Rosuvastatin

  • FDA Safety Communication on Simvastatin and SLCO1B1 (2011)
  • CPIC Guidelines for Simvastatin and SLCO1B1 (2014)
  • PharmGKB SLCO1B1 Variant Information

Thiopurine Medications (TPMT/NUDT15)

Medications: 6-Mercaptopurine, Azathioprine

  • CPIC Guidelines for Thiopurines and TPMT/NUDT15 (2018)
  • FDA Labeling for Azathioprine - Boxed Warning
  • DPWG Guidelines for Thiopurines

DPYD Medications (Chemotherapy)

Medications: 5-Fluorouracil, Capecitabine

  • CPIC Guidelines for Fluoropyrimidines and DPYD (2023)
  • FDA Drug Labeling for 5-FU and Capecitabine
  • Clinical Pharmacogenetics Implementation Consortium (CPIC) Recommendations

Other Medications

Warfarin (CYP2C9, VKORC1)

  • CPIC Warfarin Guidelines
  • FDA Warfarin Labeling

Tacrolimus (CYP3A5)

  • CPIC Tacrolimus Guidelines (2023)
  • Clinical Transplantation Guidelines

Abacavir (HLA-B*57:01)

  • FDA Requirements for HLA-B*57:01 Testing
  • DHHS HIV Treatment Guidelines

Carbamazepine (HLA)

  • FDA Warnings for HLA-B*15:02
  • CPIC Carbamazepine Guidelines

Clinical Resources

PharmGKB

Comprehensive database of gene-drug variants and clinical guidelines

pharmgkb.org

ClinicalTrials.gov

Database of clinical trials for pharmacogenomics research

clinicaltrials.gov

FDA Adverse Event Reporting

Database of drug safety reports and pharmacogenomic adverse events

FAERS Database

CPIC

Clinical pharmacogenetics implementation guidelines

cpicpgx.org

GeneTests

Directory of genetic testing laboratories and clinics

NCBI GeneTests

dbSNP

Database of single nucleotide polymorphisms

NCBI dbSNP

Important Disclaimer

The information provided on this website is for educational purposes only and should not be considered medical advice. Always consult with a qualified healthcare provider before making any decisions about your medications or treatment.

Key Points to Remember:

  • Genetic testing should be ordered by a healthcare provider
  • Results should be interpreted by a qualified professional
  • Never stop or change medications without consulting your doctor
  • Drug-gene interactions are only one factor in medication selection

Last updated: February 2026 | This website is not affiliated with any of the organizations listed above. All trademarks belong to their respective owners.